Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied
semaglutide is a peptide Conclusion# Orforglipron and semaglutide each have distinct advantages
Tchang: The majority of FDA-approved peptides, like insulin and GLP-1s, are taken in the form of injections
If approved, orforglipron would be the first oral medication that directly competes with injectable GLP-1 therapies on efficacy
It creates a synergistic effect with GHK thanks to the growth factors it contains
What questions would you like to ask your provider today
US$ 26.10
US$ 27.91
US$ 27.53
US$ 27.85
US$ 25.25
